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This Month in the Journal
This month in the Journal, David Kelsell and colleagues
have contributed a review on the connexin family of
proteins and their relationship to skin disease and hear-
ing impairment. This work summarizes which connex-
ins—and which mutations in the connexin genes—are
involved in particular inherited disorders, and it high-
lights the importance of gap junctions in the epidermis
and the inner ear.
SOST, a Novel Gene Mutated in Sclerosteosis, by
Brunkow et al. (p. 577)
Sclerosteosis is a bone-overgrowth syndrome that par-
ticularly affects the skull and that leads to widening of
the calvarium (i.e., the domelike part of the skull), with
a resulting increase in intracranial pressure, as well as
to a compression of the cranial nerves that can lead to
deafness and facial palsy. The great majority of patients
affected with sclerosteosis are from the Afrikaner pop-
ulation of South Africa, and the concentration of the
disease in this population is believed to be due to a
founder mutation. Brunkow et al. have identified scle-
rosteosis-associated mutations in a previously uniden-
tified gene, which they term “SOST,” on chromosome
17q12-q21. As predicted, all of the Afrikaner patients
in the study carry the same mutation, a nonsense mu-
tation near the amino terminus of the predicted protein.
An affected individual from Senegal has a SOST mu-
tation that leads to aberrant splicing and, possibly, to
nonsense-mediated decay of the message. The function
of the protein encoded by SOST is unknown, but the
authors speculate that it might be a negative regulator
of a protein important for postnatal bone formation.
They further suggest that, if their model is true, this
protein could be considered as a potential target for the
development of therapies aimed at bone-loss disorders;
inhibiting this negative regulator of bone deposition
could yield increased bone density in people with osteo-
porosis and related disorders.
IKBKAP Mutation Causes Familial Dysautonomia, by
Slaugenhaupt et al. (p. 598); and Familial
Dysautonomia Is Caused by Mutations of IKAP
(Report), by Anderson et al. (p. 753)
In this issue, two groups report that mutations in the
IKBKAP gene, encoding the protein IKAP, cause familial
dysautonomia (FD), an autosomal recessive disorder
that is found almost exclusively in people of Ashkenazi
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Jewish origin. Affected individuals show poor develop-
ment of and degeneration of the sensory and autonomic
nervous systems, with symptoms including abnormal
sweating, hypertension, difficulty in feeding and sucking,
gastrointestinal dysfunction, and insensitivity to pain.
These complementary articles illustrate how the same
results can be achieved through different processes. The
group led by Berish Rubin at Fordham University (see
the Anderson et al. report) used the human genome se-
quence to identify mRNAs encoded in the area of the
FD locus. Reverse transcriptase–PCR products for these
messages were compared, for size and single-strand con-
formation polymorphisms, in a control individual and
one homozygous for the major FD haplotype. One tran-
script in the region was found to be shorter in these
patients than in controls; this was the IKBKAP message.
In contrast, Jim Gusella’s group at Massachusetts Gen-
eral Hospital (see the article by Slaugenhaupt et al.) used
exon trapping and cDNA selection to clone all of the
genes in the FD critical region. A screen for mutations
in these genes led to the identification of several single-
nucleotide polymorphisms that were used to narrow the
candidate interval. The complete sequence of this smaller
critical region was compared in a patient homozygous
for the major FD haplotype and several controls. Only
one unique change was identified in patients, and it was
located in IKBKAP. The major FD mutation, which ac-
counts for 99.5% of disease chromosomes, results in
aberrant splicing of the IKBKAP RNA and, thus, to loss
of one of the exons of the mRNA. Whereas Slaugen-
haupt et al. found tissue-specific expression of this splic-
ing defect, Anderson et al. detected both a shortened
transcript and a truncated protein in lymphoblasts. A
second, much less common mutation, R696P, was found
in a consensus phosphorylation site. Anderson et al.
demonstrated that this substitution resulted in a reduced
level of phosphorylation for this protein. The normal
function of IKAP is not well understood, so it is not
clear how these mutations lead to disease. However, the
discovery of the mutations corresponding to both the
major and minor 2 FD haplotypes will greatly increase
the efficiency of genetic testing for this disease.
Analyses of FOXC1 Missense Mutations, by Saleem et
al. (p. 627)
In the February 2001 issue of the Journal, Nishimura et
al. (68:364–372) found several FOXC1 mutations in
people with congenital anterior-chamber defects of the
eye. Approximately half of these mutations were pre-
dicted to lead to truncated proteins. In addition, a du-
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plication of the region containing FOXC1 was found in
two affected families. The discovery of these mutations
suggested that tight regulation of FOXC1 levels is crucial
for proper ocular development. Following up on this
story, we have an article by Saleem et al. They studied
the effects of five different missense mutations on
FOXC1’s function as a transcription factor. These mu-
tations are associated with Axenfeld-Rieger anomaly, a
group of disorders characterized by defects in the an-
terior eye segment. Structural models based on the rat
Genesis protein predict that none of the mutations dis-
rupts the FOXC1 structure. In biochemical assays, the
mutations proved to be variously affected at the level of
protein stability, DNA binding, and transactivation abil-
ity. Although, when compared with wild-type protein,
the defects in the mutant proteins range from a 95%
decrease in protein levels to a 40% reduction in tran-
sactivation activity, all of the mutations led to an indis-
tinguishable phenotype. These results lend further sup-
port to the idea that tight regulation of FOXC1 levels
is important for proper development of the eye.
Enzyme Replacement in Fabry Disease, by Eng et al.
(p. 711)
In our January issue (68:14–25), Robert Desnick’s group
reported a successful preclinical study of enzyme re-
placement in Fabry mice. This month, they report the
next stage in this work, a phase 1/2 clinical trial. To
date, treatment for Fabry disease, a deficiency of a-ga-
lactosidase A activity, consists of symptom management
for pain and for complications of the cardiac, renal, and
cerebrovascular systems, which are due to the accu-
mulation of globotriaosylceramide (GL-3). In this paper,
Eng et al. report that infusion of recombinant human
a-Gal A leads to rapid, dose-dependent decreases in
plasma GL-3. Clearance of GL-3 from tissues was more
variable but generally decreased in the liver, skin, heart,
and kidney. Patients participating in the trial reported
significant improvement in overall pain and general
health. A double-blind study is needed to further eval-
uate the efficacy of this treatment as a therapy for Fabry
disease.
Clonal Expansion of mtDNA, by Elson et al. (p. 802)
In this issue, Elson et al. have contributed work designed
to model in single cells the accumulation of mtDNA
mutations. Although the overall level of mtDNA mu-
tations remains fairly low in older people, individual
cells may contain high levels of a single, mutated mtDNA
species. Several models have been proposed to explain
this finding, and most of them invoke a selective mech-
anism that leads to preferential replication of the mu-
tated mtDNA molecules. Elson et al. perform simula-
tions to examine the clonal accumulation of mutant
mtDNA in single postmitotic cells. The simulations show
that a gradual increase in the number of cells containing
a high proportion of mutant mtDNA can result simply
from random intracellular drift.
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